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Abstract
Aims—In the present study we evaluated the antiviral activity of subtilosin, a cyclical peptide
isolated from Bacillus amyloliquefaciens, against herpes simplex virus type 2 (HSV-2) in cell
cultures and we investigated subtilosin mode of action.
Methods and Results—We determined, using a virus yield inhibition assay, that non cytotoxic
concentrations of subtilosin inhibit HSV-2 replication in Vero cell cultures. Subtilosin strongly
inhibited extracellular and total virus production even when it was added at 8 h post-infection
indicating that not only virus release but also viral particle formation is impeded by the antiviral
peptide. Although viral glycoprotein gD level of expression is not affected by the bacteriocin, an
altered pattern of gD intracellular localization was detected by immunofluorescence assay in
subtilosin treated culture. On the other hand, at high concentrations subtilosin displays virucidal
action.
Conclusions—Subtilosin displays antiviral and virucidal actions against HSV-2. The target of
subtilosin inhibitory effect would be late stages of the viral replicative cycle such as viral
glycoprotein intracellular transport.
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Subtilosin, a ribosomally-synthesized 3.4-kDa cyclical peptide (Marx et al., 2001) produced
by both Bacillus subtilis (Babasaki et al. 1985) and Bacillus amyloliquefaciens (Sutyak et al.
2008a), is a bacteriocin that has the potential for applications in contraception and
reproductive health due to its unique properties, such as natural origin, biodegradability,
antimicrobial properties, lack of immunogenicity, overall safety, ease of production and
formulation (Sutyak et al. 2008b; Noll et al. 2012; Turovskiy et al. 2012; van Kuijk et al.
2012). Previous studies have demonstrated that subtilosin reduces sperm motility in vitro in
a dose dependent fashion (Sutyak et al. 2008b). This compound also displays antimicrobial
activity against the foodborne pathogen Listeria monocytogenes Scott A (van Kuijk et al.
2012) and against bacterial vaginosis-associated pathogen Gardnerella vaginalis, including
their antibiotic-resistant forms (Noll et al. 2012; Turovskiy et al. 2012).
Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) are human viral pathogens that
cause serious clinical diseases comprising genital ulcerations, corneal blindness, cold sores
and encephalitis. Patients with immune deficiencies have an increased risk of developing
severe HSV infection and vertical transmission of HSV-1 or HSV-2 to the newborn can
cause fatal neonatal encephalitis (Chentoufi and Benmohamed 2012). Over 530 million
people worldwide are infected with HSV-2, which can cause recurrent and painful genital
lesions, being recurrent genital herpes, the most prevalent sexually transmitted disease
(STD) (Fife et al. 2008; Chentoufi and Benmohamed 2012). On the other hand,
epidemiologic studies suggest there is synergy between HSV-2 and human
immunodeficiency virus type 1 (HIV-1); HSV-2 reactivation increases HIV-1 concentrations
in plasma and genital secretions whereas co-infection with HIV-1 would increase HSV-2
transmission risk (Freeman et al. 2006; Thurman and Doncel 2012; Des Jarlais et al. 2014).
The first antiviral chemotherapy for the management of herpetic infections was treatment
with acyclovir (ACV), an analogue of the natural nucleoside guanosine. The triphosphate
form of this analogue selectively inhibits the viral DNA polymerase activity thus inhibiting
viral replication. Drug-resistant HSV isolates are frequently found in-vitro and in
immunocompromised patients (Choong et al. 2010; van Velzen et al. 2012). Foscarnet
(FOS), a pyrophosphate analogue, is often administered in ACV resistant HSV infections.
Nevertheless, its use is reserved to patients where other drugs fail due to its high toxicity and
low bioavailability (Chilukuri and Rosen 2003). Furthermore, it has been shown that
antiviral treatment of herpetic infection fails to completely prevent HSV and HIV
transmission (Johnston et al. 2012). Considering that even in treated patients the infection
persists during the lifetime of the host (Efstathiou and Preston 2005), the lack of an effective
vaccine (Belshe et al. 2012) and the reported emergence of HSV resistant mutants, there is a
need to develop new antiherpetic compounds with different mechanisms of action.
Interestingly, in a previous study we reported that subtilosin affects HSV-1 infectivity by
two mechanisms: the bacteriocin acts as a virucidal agent and as an inhibitor of HSV-1
multiplication in cell cultures (Torres et al. 2013). In addition to its antimicrobial properties,
subtilosin does not harm vaginal tissues, and does not interfere with the healthy vaginal
lactobacilli (Sutyak et al. 2008b; Noll et al. 2012; Torres et al. 2013). Therefore, subtilosin
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is a promising non-toxic spermicide and has concomitant antimicrobial properties that may
promote healthy vaginal microbiota. In the present study we examined the susceptibility of
HSV-2 to subtilosin treatment in cell cultures and explored subtilosin mode of action.
Materials and Methods
Compounds
Subtilosin was purified from cultures of Bacillus amyloliquefaciens KATMIRA1933, as
previously described by Sutyak et al. (Sutyak et al. 2008a). Essentially, the overnight
culture’s supernatant was filter-sterilized (0.45 μm filter, Millipore, Billerica, MA, USA),
concentrated using 30% ammonium sulfate, re-suspended in water and fractionated using
Sep-Pak® Light C18 cartridges (Waters, Milford, MA, USA). The sample was subjected to
the step-gradient Tricin-SDS PAGE (Bio-Rad, Hercules, CA, USA) and silver-stain
visualized as a single band. In the overlay test with the bacteriocin-sensitive reference strain
of Micrococcus luteus this PAGE protein band produced a single zone of inhibition (data not
shown). Subtilosin was diluted with maintenance medium (MM) consisting of minimum
essential medium (MEM) (Gibco, Carlsbad, CA, USA) with 2% inactivated fetal bovine
serum and 50µg/mL of gentamycin.
Cells and viruses
African green monkey kidney (Vero) cells were grown as monolayers in MEM
supplemented with 5% inactivated fetal bovine serum and 50µg/mL of gentamycin. HSV-2
strain G was obtained from the American Type Culture Collection (Rockville, MD, USA).
Virus stock was prepared in Vero cells.
Cell cytotoxicity assay
To assess the effect of subtilosin on cell viability, confluent monolayers of Vero cells grown
in 96-well culture plates, were incubated with different concentrations of subtilosin for 48 h
at 37°C. Then, cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT, Sigma-Aldrich, St. Louis, MO) procedure (Denizot and Lang
1986). Cytotoxicity was expressed as the 50% cytotoxic concentration (CC50) which is the
concentration of subtilosin that reduced cell viability by 50% with respect to the cellular
control.
Virus yield inhibition assay
Antiviral activity was evaluated by a virus yield inhibition assay. To this end, Vero cells,
grown in 24-well culture plates, were infected with HSV-2 at a multiplicity of infection
(m.o.i.) of 1 PFU/cell. After 1 h of adsorption at 37°C, virus inoculum was discarded and
cells were covered with MM (control) or MM containing serial dilutions of subtilosin. After
24 h of incubation at 37°C, the supernatants were harvested and extracellular virus yields
were determined by a plaque formation assay. The antiviral activity was expressed as the
50% effective concentration (EC50), i.e. the compound concentration of subtilosin required
to reduce virus yield by 50% compared to the untreated infected culture. The selectivity
index (SI) was calculated as the ratio between CC50 and EC50 values.
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To assay virucidal activity of the bacteriocin, HSV-2 was incubated with subtilosin at
concentrations ranging from 25 to 200μg/mL or MM for 90 min at 37°C. After the
incubation period, aliquots were conveniently diluted in MM and remaining infectivity was
determined by plaque assay on Vero cells.
Time of addition experiment
Subtilosin (50μg/mL) was added to Vero cells, either during 6 h before the infection with
HSV-2 (m.o.i.=1) or at 1, 3, 5 or 8 h post-infection (p.i.) Cultures were incubated up to 24 h
p.i. and at that time supernatants were harvested to assess extracellular virus titer. Another
set of identically infected-treated cultures were subjected to two freeze-thaw cycles,
followed by low-speed centrifugation in order to quantify total (extracellular and
intracellular) viral infectivity. Virus titers were determined by plaque formation assay.
Indirect immunofluorescence assay
Vero cells grown on glass coverslips were infected with HSV-2 at an m.o.i. of 1 PFU/cell.
After 1 h adsorption at 37°C, cultures were incubated in MM containing or not subtilosin 25,
50 or 100μg/mL and incubated at 37°C for 24 h. After the removal of culture supernatants
cells were washed with cold PBS, fixed with cold methanol (20 min at −20°C) and then
incubated with a mouse monoclonal antibody reactive against gD viral glycoprotein (Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA) for 45 min at 37°C. The indirect staining
was carried out by using goat anti-mouse immunoglobulins conjugated to FITC (Sigma
Aldrich, St. Louis, MO, USA). Fluorescent cells were photographed with a Zeiss
microscope with epifluorescence optics.
Western blot assay
Vero cells were infected with HSV-2 (moi=1) and after virus adsorption cells were
incubated in MM containing or not subtilosin 25, 50 or 100μg/mL and incubated at 37°C for
24 h. Then cells were lysed and samples were subjected to SDS-PAGE and transferred to
PVDF membrane (Perkin Elmer Life Sciences, Inc., Waltham, MA, USA) in a dry system
(LKB Multiphor II, Pharmacia, Sweden). Viral glycoprotein gD was revealed using mouse
anti-gD (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and GAPDH, used as
loading control, was detected with mouse anti-GAPDH (Abcam, United Kingdom).
Peroxidase-conjugated anti-mouse immunoglobulin G (Promega, Madison, WI, USA) was
used as secondary antibody. The intensities of protein bands, visualized by
chemiluminescence detection, were quantified by using Image J software and the relative
intensity gD/GAPDH was calculated for each sample.
Statistical analysis
The 95 % confidence intervals (CI) of virus titers were calculated according to Poisson
distribution.
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Antiviral activity of subtilosin against HSV-2
First, we evaluated the effect of treatment with different concentrations of subtilosin on
Vero cell viability using the MTT method. The CC50 value of subtilosin in Vero cells was
316.8 µg/mL. Then we performed a virus yield inhibition assay using non-cytotoxic
concentrations of subtilosin. A dose-dependent inhibition of virus yield was observed in
subtilosin treated cultures (Figure 1). At 25μg/mL, subtilosin inhibited virus replication by
almost 90%, whereas at 200μg/mL a reduction over 99.9% in virus titer was achieved
(Figure 1). The EC50 and SI values of subtilosin against HSV-2 were 18.2μg/mL and 17.4,
respectively.
Virucidal action of subtilosin
Taking into account previous studies that showed that at high concentrations subtilosin
display virucidal activity against HSV-1 (Torres et al. 2013), we evaluated the effect of
subtilosin on HSV-2 particles by incubating aliquots of viral stock with different
concentrations of subtilosin during 90 min at 37°C. As can be seen in Fig. 2, at the highest
concentration tested (200μg/mL), subtilosin exhibited a direct inactivating effect on viral
particles since after 90 min of treatment a 99,99% reduction of HSV-2 infectivity was
observed. However, at 100, 50 or 25μg/mL, concentrations that displayed antiviral activity
(Figure 1), subtilosin showed no relevant virucidal effect (Figure 2).
Characterization of subtilosin antiviral activity
To characterize subtilosin inhibitory action against HSV-2, a time of addition experiment
was performed. Vero cells were treated with subtilosin (50μg/mL) for 6 h prior to infection
or at different times after infection. In all cases, extracellular and total virus production was
determined at 24 h p.i. Subtilosin treatment of cells before infection did not affect virus
production indicating that the peptide does not induce an antiviral state on the cell culture.
On the contrary, the presence of subtilosin from 1, 3, 5 or 8 h p.i reduced total virus titer by
approximately 6 log units and the amount of infectious virus released to the extracellular
medium was also strongly inhibited (Figure 3). The same level of reduction in virus
production was observed when subtilosin was added at 1 or 8 h p.i., thus a possible
explanation for these results is that a late stage on the viral replicative cycle would be
blocked by subtilosin.
In order to further investigate which is the step of viral replication affected by subtilosin, we
performed an IF assay to analyze the effect of the bacteriocin on viral protein expression
employing a monoclonal antibody that recognizes gD glycoprotein. We observed that gD
was localized predominately in the perinuclear region of cells treated with subtilosin,
whereas in untreated cells a more diffuse and homogenous pattern of cytoplasmic
fluorescence was detected. Changes in gD intracellular distribution were more evident in
cultures treated with the highest concentration of subtilosin assayed (Figure 4 b). To
determine whether treatment with subtilosin also affects gD production, we performed a
comparative analysis of gD total level of expression between cultures treated with different
concentrations of subtilosin and untreated infected cells. The analysis by western blot shown
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in figure 5 revealed similar gD levels in treated and untreated cells indicating that the
antimicrobial peptide does not impair viral protein synthesis. Altogether these results
suggest that subtilosin would not affect gD production but interferes with gD intracellular
transport therefore affecting formation of mature viral particles.
Discussion
The lifelong HSV-2 infection is the principal cause of genital ulcer disease and it is also a
contributing factor in the increase of acquisition and transmissibility of HIV infection
(Gottlieb et al. 2014; Des Jarlais et al. 2014). In the last years, great efforts have been made
to develop new antiviral molecules effective against HSV including those viral strains that
are resistant to nucleoside analogues (Wald et al. 2014). In a previous work we have
described the ability of subtilosin to inhibit the multiplication of ACV-susceptible and ACV-
resistant strains of HSV-1 (Torres et al. 2013). Here we demonstrate that subtilosin is also
an effective inhibitor of HSV-2 multiplication and we further characterize the antiviral mode
of action of this bacterial peptide.
Although antiviral activity of several antimicrobial peptides isolated from different bacteria
genera has been previously reported (Wachsman et al. 1999, 2003; Serkedjieva et al. 2000;
Todorov et al. 2005, 2010; Saeed et al. 2007; Férir et al. 2013) no virucidal effect was
described for these bacteriocins and up to now much remains unknown about their inhibitory
mechanism of action. CRL5, peptide isolated from Enterococcus faecium, exhibits an
inhibitory effect on HSV-1 late viral protein synthesis (Wachsman et al. 2003) whereas the
lantibiotic peptide Labyrinthopeptin A1 produced by Actinomadura namibiensis blocks an
early after-adsorption step of HIV multiplication (Férir et al. 2013).
Our results show that pre-treatment with subtilosin did not protect cells from infection. This
indicates that subtilosin should be present during viral multiplication to exert its inhibitory
action and also suggests that the bacteriocin does not cause an irreversible effect on host cell
functions. However, the addition of subtilosin after HSV-2 infection strongly inhibited both
extracellular and total virus production, indicating that not only virus release but also viral
particle formation is blocked by bacteriocin treatment. The same level of inhibition was
achieved when subtilosin was added between 1 and 8 h p.i. indicating that early events of
HSV-2 multiplication cycle are not affected by the bacteriocin.
Furthermore, the analysis of the expression of viral glycoprotein gD showed that although
gD production is not affected by the bacteriocin an altered pattern of gD intracellular
localization in subtilosin treated cultures was observed suggesting that subtilosin would
affect gD intracellular transport. Future studies will be necessary to establish the precise
cellular compartment in which gD accumulates after subtilosin treatment. Taking together
these results indicate that the target of subtilosin antiviral action are late stages of virus
replication, thus hindering viral particle formation.
Besides its inhibitory effect and in coincidence with the results obtained with HSV-1 (Torres
et al. 2013), at high concentrations, subtilosin also exhibits virucidal action against HSV-2.
Altogether our results show that subtilosin mode of antiviral action seems to be clearly
Quintana et al. Page 6













different to those previously described for other bacteriocins (Serkedjieva et al. 2000;
Wachsman et al. 2003; Férir et al. 2013).
Control of transmission of STDs includes the use of topically applied microbicides that
inactivate the relevant pathogens, thus virucidal agents provides a good source of developing
new microbicidal formulations. Bacteriocins are attractive natural alternatives to classic
antibiotics and virucidal agents, which could be used for the treatment of bacterial and viral
infections. The ability of subtilosin to inactivate both HSV-1 and HSV-2 particles, together
with its spermicidal activity and safety of subtilosin based nanofibers for use on human skin
tissues (Sutyak et al. 2008b; Torres et al. 2013) makes this peptide a promissory candidate
to be included in new studies concerning the design of nanofiber systems containing a
combination of antimicrobial and anti-inflammatory drugs to be proved in animal models.
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Significance and Impact of Study
Given its antimicrobial activity and its safety for human tissues, subtilosin could
represent a valuable alternative to be considered in the development of new microbicide
formulations.
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Figure 1. Dose-dependent inhibition of HSV-2 multiplication by subtilosin
Vero cells infected with HSV-2 (m.o.i. =1) were incubated with different concentrations of
subtilosin. At 24 h p.i. virus yield was quantified by plaque assay. Data represent mean
values from duplicate determinations ± standard deviation (SD).
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Figure 2. Virucidal activity of subtilosin
HSV-2 suspensions were incubated with different concentrations of subtilosin during 90 min
at 37°C. Remaining infectivity was determined by plaque formation assay. Data represent
mean values from duplicate determinations ± SD.
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Figure 3. Effect of time of addition of subtilosin on HSV-2 production
Vero cells were treated with subtilosin during 6 h previous to infection (−6) or were
incubated with subtilosin from different times after infection (1, 3, 5 or 8 h p.i.). At 24 h p.i.
extracellular (grey bars) and total virus (black bars) production were determined. U =
untreated infected culture. Data are mean values of virus titers from duplicate determinations
± 95% CI.
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Figure 4. Intracellular localization of gD glycoprotein in subtilosin treated cells
Cytoplasmic immunofluorescence staining of HSV-2 infected Vero cells in the absence (a)
or in the presence of 100μg/mL (b), 50μg/mL (c) or 25μg/mL (d) subtilosin. Magnification
400×.
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Figure 5. gD production in subtilosin treated cells
HSV-2 infected Vero cells were treated with different concentrations of subtilosin and at 24
h p.i. the expression of viral protein gD and cellular protein GAPDH, used as loading
control, was assessed by Western blot. The relative intensity of gD band with respect to
GAPDH band for each sample of one representative experiment is shown.
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